WHO issues global alert on rare vision loss linked to popular diabetes, weight loss drugs
Geneva: The World Health Organization (WHO) has issued a global safety alert warning of a rare but potentially irreversible vision condition associated with popular diabetes and weight-loss drugs containing semaglutide, including Ozempic, Rybelsus, and Wegovy.
The alert, released on 27 June, highlights the risk of non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can lead to sudden, painless, and irreversible loss of vision, typically in one eye.
“There is currently no effective treatment available for NAION, and the vision loss is generally irreversible,” the WHO stated in its warning.
The European Medicines Agency (EMA) has already acted on this risk by updating the safety profiles of these drugs. Following a comprehensive safety review, the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) recommended that NAION be listed as a “very rare” side effect, potentially affecting up to 1 in 10,000 users.
Semaglutide, a GLP-1 receptor agonist, has seen widespread use globally for treating type 2 diabetes and obesity. However, the growing popularity of these drugs has also brought new safety concerns to light.
NAION is considered the second most common optic neuropathy after glaucoma and can present without pain, making early detection more challenging. Common symptoms include sudden vision loss and optic disc swelling.
The WHO noted that its global adverse event database, VigiBase, had received several individual case safety reports of NAION linked to semaglutide use from multiple countries. After assessing these reports during its May 2025 meeting, the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP) recommended revising semaglutide’s risk management plans.
Healthcare professionals worldwide are now being urged to inform patients about this potential risk and to remain vigilant. Patients currently using semaglutide or considering it are advised to seek immediate medical help if they experience any sudden changes in vision.
The alert is part of continued pharmacovigilance efforts around GLP-1-based medications, which have transformed diabetes and obesity care but continue to face evolving scrutiny as their use expands.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Voting begins for Assam's 126 assembly seats
_vb_85.jpeg)
Guwahati (PTI): Polling for all 126 Assam assembly constituencies began on Thursday to decide the electoral fate of 722 candidates, officials said.
In the high-stakes election, the ruling BJP is aiming for a third consecutive term in office, while the Congress seeks to wrest power after being ousted in 2016.
Polling, being held in a single phase, began at 7 am and will conclude at 5 pm. Long queues of voters were seen outside polling stations from early morning.
An electorate of 2.50 crore, including 1.25 crore women and 318 from the third gender, can exercise their franchise in 31,490 polling stations across the state.
Prominent candidates include Chief Minister Himanta Biswa Sarma, Congress state president Gaurav Gogoi, assembly Speaker Biswajit Daimary, Leader of the opposition Debabrata Saikia, AIUDF chief Badruddin Ajmal, Raijor Dal president Akhil Gogoi, and Assam Jatiya Parishad (AJP) chief Lurinjyoti Gogoi.
Several cabinet ministers, including the AGP’s Atul Bora and Keshav Mahanta, and the BPF’s Charan Boro are also in the fray.
The Congress has the highest of 99 contestants, followed by the BJP (90), AIUDF (30), NDA allies AGP (26) and BPF (11).
Opposition alliance’s Raijor Dal is contesting in 13, AJP in 10, CPI(M) in 3 and APHLC in 2. Outside the two coalitions, the AAP is contesting in 18 seats, UPPL in 18, TMC 22, JMM 16 and there are 258 independents.
The ruling NDA’s main constituents are the BJP, Asom Gana Parishad (AGP) and the Bodo Peoples’ Front (BPF) while the opposition alliance comprises the Congress, Raijor Dal, Assam Jatiya Parishad (AJP), CPI(M), All Party Hill Leaders Conference (APHLC) and CPI(ML).
The counting of votes is scheduled on May 4.
_vb_34.jpeg)
_vb_49.jpeg)
